Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter? - Wikidata - wikimedia - TriplyDB

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

http://www.wikidata.org/entity/Q38587494

about

Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.Sol-gel Silica Nanoparticles in Medicine: A Natural Choice. Design, Synthesis and Products

P2860

Q52584444-9CDE3833-13DD-468F-8CAF-D2B2DBD7456F Q58692690-4FF537D0-DC96-4908-8122-14386EC9C98D

P2860

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

http://www.wikidata.org/entity/Q38587494

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

@en

type

label

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

@en

prefLabel

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

@en

P1433

Q38587494-5CB29ECF-DB79-443C-965A-1FC9E4835E21

P1476

Q38587494-5F40A717-E993-4CE9-8D8D-CFB6902716A1

P2093

Q38587494-E913CADD-ADB7-4844-BFC2-E317F20BA7C9

P2860

Q38587494-0122F62A-576D-4F57-973B-1147573C0821

Q38587494-057D5EB4-9064-4B89-AFEE-DAB43639E509

Q38587494-06772064-863A-49E0-813E-A7650AF1C477

Q38587494-08845FA2-4F51-46E7-A42A-7972FBD300FF

Q38587494-1564AFBC-F075-4061-ADEF-EF37C83F5BD9

Q38587494-2AA7A130-1503-4974-A132-6872D75DC8C7

Q38587494-303EEB29-F0F5-4728-8BC3-49E52FB141C7

Q38587494-30ACCDE9-1569-463A-96B2-980DD852BB50

Q38587494-5133826E-B6D3-4B01-B132-D59333558C7F

Q38587494-55B569AC-F487-4FD8-9A20-E2AB8F49C553

P2888

Q38587494-ED2C1684-80C9-46CB-BBE8-70B1054EB987

P304

Q38587494-F55F87CC-F7FC-4AB0-BAB6-DE4E35D50CD7

P31

Q38587494-78E74300-0E5E-43F1-9FFD-0B6C024F5099

P356

Q38587494-0E67C7C7-8965-4F9A-A96A-F74CADC8148B

P433

Q38587494-88D467EA-38A4-4C2A-B796-23134E46999B

P478

Q38587494-491BF0B5-D7C4-4B6C-B571-46ECDD316935

P50

Q38587494-724FF1EA-8B15-42B6-9CB2-E22CDEE100BB

Q38587494-9750072F-9EA5-4C98-81B3-E4F5EE24FB5B

Q38587494-AF789CC1-C8EB-40E2-A842-99718C2ACE6F

P577

Q38587494-ED973842-3DDB-4DD7-8D30-6F5F68FF7E01

P698

Q38587494-E27DF69C-81DD-4A03-9353-4426D3C668E2

P921

Q38587494-BC75B12E-F39A-497D-A771-C3493B9CC8DF

P356

S11948-015-9705-6

P1433

Science and Engineering Ethics

P1476

Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

@en

P2093

David M Shaw

http://www.w3.org/2001/XMLSchema#string

P2860

Handling worker and third-party exposures to nanotherapeutics during clinical trials

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

The emerging nanomedicine landscape

Ethical issues in clinical trials involving nanomedicine

Building an ethical foundation for first-in-human nanotrials

Scientific research and the public trust

Can the pharmaceutical industry reduce attrition rates?

Study design in qualitative research--2: Sampling and data collection strategies.

Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

Researcher views about funding sources and conflicts of interest in nanotechnology.

P2888

s11948-015-9705-6

P304

1255-1276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11948-015-9705-6

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26373718

http://www.w3.org/2001/XMLSchema#string

P921